Influenza And Beyond: Sanofi Pasteur R&D Chief Talks Strategy

 
• By Lucie Ellis-Taitt

Sanofi Pasteur's R&D chief talks to Scrip about the integration process for Protein Sciences, a vaccine company the group acquired earlier this year in a $650m deal, and how Sanofi Pasteur is using new technologies to speed up vaccine development.

Syringe
Sanofi Pasteur to target acquired recombinant flu vaccine at 50-plus population • Source: Shutterstock

More from AI

More from Digital Technologies